AC-0058TA

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAC-0058TA
Drug Alias NameAC-0058AC-0058TA
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Acea Pharmaceutical Research Co LtdZhejiang Acea Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Acea Pharmaceutical Research Co LtdZhejiang Acea Pharmaceutical Co Ltd
Inactive CompaniesAcea Therapeutics Inc
Active IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A